Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$102.2 million.

  • Karyopharm Therapeutics' Net Income towards Common Stockholders fell 23116.66% to -$102.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$196.0 million, marking a year-over-year decrease of 15625.34%. This contributed to the annual value of -$196.0 million for FY2025, which is 15625.34% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Net Income towards Common Stockholders of -$102.2 million as of Q4 2025, which was down 23116.66% from -$33.1 million recorded in Q3 2025.
  • Over the past 5 years, Karyopharm Therapeutics' Net Income towards Common Stockholders peaked at $38.7 million during Q4 2021, and registered a low of -$102.2 million during Q4 2025.
  • Over the past 5 years, Karyopharm Therapeutics' median Net Income towards Common Stockholders value was -$36.8 million (recorded in 2022), while the average stood at -$35.3 million.
  • Per our database at Business Quant, Karyopharm Therapeutics' Net Income towards Common Stockholders skyrocketed by 18909.97% in 2021 and then tumbled by 25657.36% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Net Income towards Common Stockholders stood at $38.7 million in 2021, then tumbled by 201.92% to -$39.4 million in 2022, then fell by 6.73% to -$42.1 million in 2023, then rose by 26.67% to -$30.9 million in 2024, then plummeted by 231.17% to -$102.2 million in 2025.
  • Its last three reported values are -$102.2 million in Q4 2025, -$33.1 million for Q3 2025, and -$37.3 million during Q2 2025.